Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CUVL
Strong BuyClinuvel Pharmaceuticals Limited · Healthcare · Australia · $311M · Avg Vol: $53K/d
87
StockRankGet insider-trade alerts
Q
85
V
62
M
38
P/E (TTM)
16.6x
ROE
14.0%
D/E
0.0x
Dividend %
0.7%
COMPANY DESCRIPTION
Clinuvel Pharmaceuticals Limited is a global specialty biopharmaceutical company focused on the development of treatments for severe genetic and skin disorders. Its moat is anchored by the commercial success of its flagship photoprotective drug, SCENESSE, which serves a niche patient population with unmet medical needs.
Loading 1Y...
PRICE (1Y)-16.8%
SMA 50SMA 200
Close
$6.16
RSI (14)
41.8
52W High
$8.92
From 52W High
0.7%
SCORE BREAKDOWN
Quality
85
ROIC
22.9%93.0
ROE
14.0%80.7
GP/Assets
31.8%68.4
Op. Margin
36.6%95.1
FCF/Assets
11.8%89.5
Piotroski
498.1
Int. Cover
12.6x65.5
D/E Ratio
0.00x93.0
Current Ratio
14.64x92.2
Value
62
P/E (TTM)
16.6x66.8
EV/EBITDA
4.7x93.3
P/FCF
13.4x66.5
P/B
3.0x44.7
P/S
5.6x40.0
Div Yield
0.7%15.1
Momentum
38
52W High %
69%47.4
RS 6M
-31%30.2
SMA 50/200
0.97x52.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-26%19.0
FUNDAMENTALS
Market Cap
$311M
P/E (Forward)
—
Gross Margin
89.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CUVL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CUVL | Clinuvel Pharmaceuticals Limited(you) | $311M | 87 | Strong Buy |
| BLS.AX | BLS Pharmaceuticals Limited | $152M | 79 | Buy |
| SPL.AX | Starpharma Holdings Limited | $244M | 49 | Hold |
| NEU.AX | Neuren Pharmaceuticals Limited | $1.9B | 74 | Buy |
| TTX.AX | Tetratherix Limited | $263M | 34 | Sell |
| ATHE | Alterity Therapeutics Limited | $82M | 55 | Hold |
| KZIA | Kazia Therapeutics Limited | $155M | 36 | Hold |
| AVE.AX | Avecho Biotechnology Limited | $64M | 42 | Hold |
| RAC.AX | Racura Oncology Ltd | $302M | 11 | Strong Sell |
| PYC.AX | PYC Therapeutics Limited | $1.6B | 34 | Sell |
Peer medians: ROE -27.4% · P/E 36.9x · Gross margin 60.5%